Tenon Medical (TNON) to Release Quarterly Earnings on Thursday

Tenon Medical (NASDAQ:TNON) is projected to issue its Q3 2025 results after the market closes on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $1.2930 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

Tenon Medical (NASDAQ:TNON) last posted its earnings results on Wednesday, August 13th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.11. Tenon Medical had a negative net margin of 429.45% and a negative return on equity of 332.11%. The company had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.91 million.

Tenon Medical Price Performance

Tenon Medical stock opened at $1.20 on Tuesday. The firm has a 50 day simple moving average of $1.20 and a 200-day simple moving average of $1.16. The stock has a market cap of $10.66 million, a price-to-earnings ratio of -0.24 and a beta of 1.28. Tenon Medical has a 1-year low of $0.85 and a 1-year high of $5.85.

Institutional Trading of Tenon Medical

An institutional investor recently bought a new position in Tenon Medical stock. Jane Street Group LLC purchased a new position in shares of Tenon Medical, Inc. (NASDAQ:TNON) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,958 shares of the company’s stock, valued at approximately $29,000. Jane Street Group LLC owned approximately 0.23% of Tenon Medical as of its most recent SEC filing. 22.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on TNON shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tenon Medical in a research report on Wednesday, October 8th. Wall Street Zen downgraded Tenon Medical from a “hold” rating to a “sell” rating in a research report on Saturday, October 25th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Tenon Medical Company Profile

Tenon Medical, Inc, a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints.